159 related articles for article (PubMed ID: 26542093)
1. Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance.
Patel D; Gao Y; Son K; Siltanen C; Neve RM; Ferrara K; Revzin A
Lab Chip; 2015 Dec; 15(24):4614-24. PubMed ID: 26542093
[TBL] [Abstract][Full Text] [Related]
2. Hydrogel microfluidic co-culture device for photothermal therapy and cancer migration.
Lee JM; Seo HI; Bae JH; Chung BG
Electrophoresis; 2017 May; 38(9-10):1318-1324. PubMed ID: 28169441
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
4. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
6. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
7. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
9. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
10. Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
Hoogstraat M; Gadellaa-van Hooijdonk CG; Ubink I; Besselink NJ; Pieterse M; Veldhuis W; van Stralen M; Meijer EF; Willems SM; Hadders MA; Kuilman T; Krijgsman O; Peeper DS; Koudijs MJ; Cuppen E; Voest EE; Lolkema MP
Pigment Cell Melanoma Res; 2015 May; 28(3):318-23. PubMed ID: 25515853
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
13. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?
Porcelli L; Guida G; Tommasi S; Guida M; Azzariti A
Cancer Chemother Pharmacol; 2015 Aug; 76(2):433-8. PubMed ID: 26070258
[TBL] [Abstract][Full Text] [Related]
15. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
Zhang L; Kharbanda S; Hanfelt J; Kern FG
Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
[TBL] [Abstract][Full Text] [Related]
16. Recapitulation of in vivo-like paracrine signals of human mesenchymal stem cells for functional neuronal differentiation of human neural stem cells in a 3D microfluidic system.
Yang K; Park HJ; Han S; Lee J; Ko E; Kim J; Lee JS; Yu JH; Song KY; Cheong E; Cho SR; Chung S; Cho SW
Biomaterials; 2015 Sep; 63():177-88. PubMed ID: 26113074
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma-associated fibroblasts promoted tumor spheroid invasion on a microfluidic 3D co-culture device.
Liu T; Lin B; Qin J
Lab Chip; 2010 Jul; 10(13):1671-7. PubMed ID: 20414488
[TBL] [Abstract][Full Text] [Related]
18. High-throughput combinatorial cell co-culture using microfluidics.
Tumarkin E; Tzadu L; Csaszar E; Seo M; Zhang H; Lee A; Peerani R; Purpura K; Zandstra PW; Kumacheva E
Integr Biol (Camb); 2011 Jun; 3(6):653-62. PubMed ID: 21526262
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
20. Cellular observations enabled by microculture: paracrine signaling and population demographics.
Domenech M; Yu H; Warrick J; Badders NM; Meyvantsson I; Alexander CM; Beebe DJ
Integr Biol (Camb); 2009 Mar; 1(3):267-74. PubMed ID: 20011455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
